BUY
They provide home equipment and therapy to deal with sleep apnea and other respiratory issues. Earnings are expected to grow 75%. 2021 ROE 37% as earnings rocket up, expected to jump 85% in 2020 and 16% in 2021. PE is 18x 2020, and 22x in 2021. Positive free cash flow which should double. It could join a U.S. index which will boost the stock. $15.25 price target or 9% upside.
HOLD
Operates in South Africa. Earnings should double this year and rise 50% in 2021. There's a merger underway. They are a disciplined buyer of companies, and this new deal should be accretive. He's bullish on gold.
DON'T BUY

They compete with Xebec which he prefers. It's growing and has a backlog, but analysts still foresee negative earnings.

TOP PICK
The operate gold and copper mines in Bulgaria and Namibia. Earnings up 80% YOY, and boast a 9.2% free cash flow yield. Cash flow to grow 74% in 2020 and 17% in 2021. Price-to-cash flow is 5.9x. ROE expected this year is 21%. (Analysts’ price target is $9.23)
TOP PICK
Pays a 1.5% yield. 13% YOY sales growth and a large 12.8% free cash flow yield. Cash flow grew YOY 236%. Earnings to grow 7% this year and 5% in 2021 with a PE of 14.3x. (Analysts’ price target is $37.67)
TOP PICK
Pays a 3.5% yield at a modest payout. Boasts 26% YOY sales growth and 44% earnings. 6.4% free cash flow yield. Earnings to grow 6% in 2020 and 4% in 2021. A large 31% ROE for 2021 is expected. (Analysts’ price target is $33.58)